Strong growth predicted for ovarian cancer & IBS drug markets

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.602, 2010-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

DIMming Ovarian Cancer Growth

Current Drug Targets, Vol. 13, Iss. 14, 2012-12 ,pp. : 1869-1875

Bentham Science Publishers

Access to resources Recommend Favorite

Fertility drugs: no strong association with ovarian cancer

Reactions Weekly, Vol. 1, Iss. 1240, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell

Current Pharmaceutical Biotechnology, Vol. 19, Iss. 6, 2018-05 ,pp. : 506-513

Bentham Science Publishers

Access to resources Recommend Favorite

Growth expected in cancer, pain, COPD markets. . .

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 502, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Vitamin D Receptor is a Novel Drug Target for Ovarian Cancer Treatment

Current Cancer Drug Targets, Vol. 6, Iss. 3, 2006-05 ,pp. : 229-244

Bentham Science Publishers

Access to resources Recommend Favorite